Drug Interaction Report
1 drug interaction and 2 additional warnings found for the following 2 drugs:
- letermovir
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:letermovir trofinetide
Applies to: letermovir, trofinetide
Trofinetide may increase the blood levels and effects of letermovir.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Disease interactions
2 potential interactionsApplies to: 2 conditions, including Liver Disease and Renal Dysfunction.
Liver Disease
Moderate:letermovir
Letermovir has a moderate potential interaction with Liver Disease.
The use of letermovir is not recommended for patients with severe liver dysfunction (Child-Pugh C). No dosage adjustment of letermovir is required for patients with mild or moderate liver dysfunction (Child-Pugh A or B).
Renal Dysfunction
Moderate:letermovir
Letermovir has a moderate potential interaction with Renal Dysfunction.
Hydroxypropyl betadex present in the IV letermovir formulation is mainly eliminated by glomerular filtration. Decreased elimination of hydroxypropyl betadex has been reported in patients with severe renal dysfunction. Serum creatinine levels should be closely monitored in patients with CrCl less than 50 mL/min using letermovir injection because accumulation of the IV vehicle (hydroxypropyl betadex) could occur. In patients with CrCl greater than 10 mL/min, no dosage adjustment of letermovir is required based on renal dysfunction. The safety of letermovir in patients with end-stage renal disease (CrCl less than 10 mL/min), including patients on dialysis, is unknown.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.